Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
6 Months : From Apr 2019 to Oct 2019
By Michael Dabaie
Regeneron Pharmaceuticals Inc. (REGN) said the Food and Drug Administration approved Eylea injection to treat all stages of diabetic retinopathy.
The company said Eylea improves diabetic retinopathy and prevents worsening disease that can lead to blindness. Diabetic retinopathy is the leading cause of blindness among working-aged American adults, Regeneron said.
The FDA approval of Eylea as a treatment for diabetic retinopathy was based on six-month and one-year results from Panorama, a randomized, multi-center, controlled Phase 3 trial that enrolled 402 patients.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
May 13, 2019 15:14 ET (19:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.